EAM
CRVS icon

Eventide Asset Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Eventide Asset Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-550,000
Closed -$8.05M – 309
2026
Q1 		$8.05M Buy
+550,000
New +$8.78M 0.13% 149

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Eventide Asset Management's CRVS Position: Q2 2026 in Review

Eventide Asset Management sold out of Corvus Pharmaceuticals (CRVS) in Q2 2026, closing a stake of 550,000 shares — an estimated $8.05M sold.

Eventide Asset Management first reported a position in CRVS in Q1 2026 and held it in 1 quarter. The position peaked at $8.05M in Q1 2026. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Eventide Asset Management reported no remaining Corvus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Eventide Asset Management sold 550,000 Corvus Pharmaceuticals shares in Q2 2026, an estimated $8.05M.
  • Eventide Asset Management first reported a position in Corvus Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Eventide Asset Management's Corvus Pharmaceuticals position peaked at $8.05M in Q1 2026.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.